
Novo Nordisk invests €2.1bn in production expansion
While Novo Nordisk’s main competitor Eli Lilly in the emerging market of effective drugs that fight obesity announced an investment of €11bn...

Pierre Fabre Laboratories acquires Vertical Bio
The acquisition of Vertical Bio AG for an undisclosed amount of money allows Pierre Fabre Laboratories to...

Alfasigma SpA set to take over Galapagos programme
Under the planned agreement, Alfasigma SpA will pay €50m upfront, milestones totaling €120m and mid-single to mid-double digit royalties on European...

Aboleris Pharma bags €27.3m in Series A Financing
AbolerIS Pharma SA’s financing was led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with...

BioInnovation Institute Boosts Six Life Science Companies
The Venture House initiative aims at propelling former Venture Lab participants into the next phase of their development. “These six companies have...

Orakl Oncology SA raises €3m to advance tumour modelling
French precision oncology start-up Orakl Oncology has raised €3m in a seed financing round led by Speedinvest with additional investment from...

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...